AADI:NSD-Aadi Bioscience Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 19.32

Change

-0.73 (-3.64)%

Market Cap

USD 0.47B

Volume

0.06M

Avg Analyst Target

USD 48.00 (+148.45%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aadi Bioscience Inc (AADI) Stock Analysis:
Based on the Aadi Bioscience Inc stock forecasts from 4 analysts, the average analyst target price for Aadi Bioscience Inc is USD 48.00 over the next 12 months. Aadi Bioscience Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aadi Bioscience Inc is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Aadi Bioscience Inc’s stock price was USD 19.32. Aadi Bioscience Inc’s stock price has changed by -3.18 % over the past week, -9.14 % over the past month and +0.00 % over the last year.

About

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluati ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+5.23 (+1.73%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

+10.57 (+3.17%)

USD87.92B 10.55 8.07
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.18%)

USD67.82B 10.14 7.73
VRTX Vertex Pharmaceuticals Incorpo..

-0.64 (-0.31%)

USD48.34B 24.52 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-31.73 (-9.17%)

USD33.38B N/A N/A
SGEN Seagen Inc

-7.93 (-5.00%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.80%)

USD25.21B 56.53 6.26
ALNY Alnylam Pharmaceuticals Inc

-11.49 (-6.28%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AADI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.47B 63% D 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -87.30 95% A 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -15.78% 78% C+ 30% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.73 87% B+ 81% B-
Short Percent 0.86% 88% B+ 76% C
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.